Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

Although tumor progression involves processes such as tissue invasion that can activate inflammatory responses, the immune system largely ignores or tolerates disseminated cancers. The mechanisms that block initiation of immune responses during cancer development are poorly understood. We report here that constitutive activation of Stat-3, a common oncogenic signaling pathway, suppresses tumor expression of proinflammatory mediators. Blocking Stat-3 in tumor cells increases expression of proinflammatory cytokines and chemokines that activate innate immunity and dendritic cells, leading to tumor-specific T-cell responses. In addition, constitutive Stat-3 activity induces production of pleiotropic factors that inhibit dendritic cell functional maturation. Tumor-derived factors inhibit dendritic cell maturation through Stat-3 activation in progenitor cells. Thus, inhibition of antitumor immunity involves a cascade of Stat-3 activation propagating from tumor to dendritic cells. We propose that tumor Stat-3 activity can mediate immune evasion by blocking both the production and sensing of inflammatory signals by multiple components of the immune system.

[1]  S. Akira,et al.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.

[2]  H. Schreiber,et al.  Multiple tumour-specific antigens expressed on a single tumour cell , 1983, Nature.

[3]  D. Pardoll,et al.  CD 40-independent Pathways of T Cell Help for Priming of CD 8 1 Cytotoxic T Lymphocytes , 2000 .

[4]  E. Jaffee,et al.  Cancer Vaccines , 1997, Current protocols in human genetics.

[5]  Hua Yu,et al.  A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.

[6]  P. Matzinger,et al.  Is cancer dangerous to the immune system? , 1996, Seminars in immunology.

[7]  L. Kanz,et al.  Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. , 2000, Cancer research.

[8]  R. Locksley,et al.  The Instructive Role of Innate Immunity in the Acquired Immune Response , 1996, Science.

[9]  M. Jaroszeski,et al.  Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.

[10]  T. Yeatman,et al.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[12]  R. Jove,et al.  Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.

[13]  Ira Mellman,et al.  Dendritic Cells Specialized and Regulated Antigen Processing Machines , 2001, Cell.

[14]  R. Steinman Inaugural Article : avoiding horror autotoxicus. The importance of dendritic cells in peripheral T cell tolerance , 2002 .

[15]  D. Carbone,et al.  Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells , 1996, Nature Medicine.

[16]  C. Janeway,et al.  Innate immunity: impact on the adaptive immune response. , 1997, Current opinion in immunology.

[17]  Michel C. Nussenzweig,et al.  Avoiding horror autotoxicus: The importance of dendritic cells in peripheral T cell tolerance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Rolf M. Zinkernagel,et al.  Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction , 2001, Nature.

[19]  S. Akira,et al.  Keratinocyte‐specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis , 1999, The EMBO journal.

[20]  C. Meijer,et al.  Prostanoids Play a Major Role in the Primary Tumor-Induced Inhibition of Dendritic Cell Differentiation , 2002, The Journal of Immunology.

[21]  D. Link,et al.  STAT-3 activation is required for normal G-CSF-dependent proliferation and granulocytic differentiation. , 2001, Immunity.

[22]  D. Pardoll,et al.  Cd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes , 2000, The Journal of experimental medicine.

[23]  R. DePinho,et al.  STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.

[24]  E. Jaffee,et al.  Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. , 2000, Immunity.

[25]  J. Turkson,et al.  Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation* , 2001, The Journal of Biological Chemistry.

[26]  M. Kripke,et al.  Mechanisms of syngeneic tumor rejection. Susceptibility of host- selected progressor variants to various immunological effector cells , 1982, The Journal of experimental medicine.

[27]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[28]  C. Janeway Approaching the asymptote? Evolution and revolution in immunology. , 1989, Cold Spring Harbor symposia on quantitative biology.

[29]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[30]  M. Bartoli,et al.  The FASEB Journal express article 10.1096/fj.02-1084fje. Published online June 17, 2003. VEGF differentially activates STAT3 in microvascular endothelial cells , 2022 .

[31]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[32]  C. Uyttenhove,et al.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression , 1983, The Journal of experimental medicine.

[33]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[34]  S. Rosenberg,et al.  Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma , 1997, The Journal of experimental medicine.

[35]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[36]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[37]  J. Darnell,et al.  Stat3 Recruitment by Two Distinct Ligand-induced, Tyrosine-phosphorylated Docking Sites in the Interleukin-10 Receptor Intracellular Domain* , 1996, The Journal of Biological Chemistry.

[38]  J. Turkson,et al.  Stat3 Activation by Src Induces Specific Gene Regulation and Is Required for Cell Transformation , 1998, Molecular and Cellular Biology.

[39]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.